CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Theseus
Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage
biopharmaceutical company focused on improving the lives of cancer
patients through the discovery, development and
commercialization of transformative targeted therapies, today
announced that Tim Clackson, Ph.D., President and Chief
Executive Officer of Theseus, will participate in a virtual
fireside chat for the 11th Annual SVB Leerink Global
Healthcare Conference, taking place February 14-18, 2022.
Presentation Details:
Event: 11th
Annual SVB Leerink Global Healthcare Conference
Date / Time: Friday, February
18th at 2:20pm
ET
Format: Live Fireside Chat
A live webcast will be available in the Events section of the
company's investor relations website at ir.theseusrx.com and
archived for 30 days following the presentation.
Management will also be participating in one-on-one investor
meetings throughout the conference. Investors interested in
scheduling a meeting with the Theseus management team should
contact their SVB Leerink representative.
About Theseus Pharmaceuticals, Inc.
Theseus is a
clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients through the discovery, development and
commercialization of transformative targeted therapies. Theseus is
working to outsmart cancer resistance by developing pan-variant
tyrosine kinase inhibitors (TKIs) to target all known classes of
cancer-causing and resistance mutations that lead to variants in a
particular protein in a given type of cancer. Theseus' lead product
candidate, THE-630, is a pan-variant KIT inhibitor for the
treatment of patients with advanced gastrointestinal stromal tumors
(GIST), whose cancer has developed resistance to earlier lines of
kinase inhibitor therapy. Theseus is also developing a
fourth-generation, selective epidermal growth factor receptor
(EGFR) inhibitor for C797S-mediated resistance to first- or
later-line osimertinib treatment in patients with non-small cell
lung cancer (NSCLC). For more information,
visit www.theseusrx.com.
Media Contact
Amy Jobe,
Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contact
Christen
Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-virtually-in-svb-leerink-global-healthcare-conference-301477829.html
SOURCE Theseus Pharmaceuticals